Why MRNA Stock Is Retreating
RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...
Moderna Stock Is Sliding Wednesday: Here's Why
Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...
Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.
Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.
Moderna's stock is falling. Goldman Sachs says it's no longer a buy.
Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months. Moderna shares (MRNA) fell 2% in ...
Moderna down as Goldman Sachs downgrades on revenue outlook
Moderna (NASDAQ:MRNA) traded lower in the premarket on Wednesday after Goldman Sachs downgraded the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook.
Breaking Down Gilead Sciences: 22 Analysts Share Their Views
In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...